Stevens-Johnson Syndrome Induced by Vandetanib
Annals of Dermatology
; : S343-S345, 2011.
Article
en En
| WPRIM
| ID: wpr-165614
Biblioteca responsable:
WPRO
ABSTRACT
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Piperidinas
/
Quinazolinas
/
Proteínas Tirosina Quinasas
/
Síndrome de Stevens-Johnson
/
Carcinoma de Pulmón de Células no Pequeñas
/
Receptores de Factores de Crecimiento Endotelial Vascular
/
Proliferación Celular
/
Diarrea
/
Receptores ErbB
/
Hipertensión
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Annals of Dermatology
Año:
2011
Tipo del documento:
Article